Cargando…

Choosing the best first-line therapy: NSCLC with no actionable oncogenic driver

Combination platinum-based therapy has been the standard of care for the treatment of advanced non-small-cell lung cancer (NSCLC). Immunotherapy has emerged and demonstrated to show benefit in the treatment of patients with advanced NSCLC. In this review, we discuss the pivotal trials that led to th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, So Yeon, Halmos, Balazs
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Future Medicine Ltd 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7399613/ https://www.ncbi.nlm.nih.gov/pubmed/32774467 http://dx.doi.org/10.2217/lmt-2020-0003

Ejemplares similares

Editorial: Immunotherapy for NSCLC with oncogenic driver variants
por: Du, Yijia, et al.
Publicado: (2022)

Effect of depression disorder on the efficacy and quality of life of first-line chemotherapy combined with immunotherapy in oncogene-driver negative NSCLC patients
por: Li, Wen, et al.
Publicado: (2022)

A Matching-Adjusted Indirect Comparison of Pembrolizumab + Chemotherapy vs. Nivolumab + Ipilimumab as First-Line Therapies in Patients with PD-L1 TPS ≥1% Metastatic NSCLC
por: Halmos, Balazs, et al.
Publicado: (2020)

Chemotherapy and/or immune checkpoint inhibitors in NSCLC first-line setting: what is the best approach?
por: Gravara, Luigi Della, et al.
Publicado: (2020)

Choosing the Best Media Platforms
Publicado: (2022)

Novel active agents in patients with advanced NSCLC without driver mutations who have progressed after first-line chemotherapy
por: Manegold, Christian, et al.
Publicado: (2017)

Choosing Actions
por: Rosenbaum, David A., et al.
Publicado: (2013)

Tranexamic acid – choosing the best dose
por: Alves, Rodrigo Leal
Publicado: (2020)

Immunotherapy in the First-Line Setting in Wild-Type NSCLC
por: Denault, Marie-Hélène, et al.
Publicado: (2021)

Nivolumab plus ipilimumab combination therapy for the first-line treatment NSCLC: evidence to date
por: Remon, Jordi, et al.
Publicado: (2019)

Why choose cyclosporin A as first-line therapy in COVID-19 pneumonia()
por: Sanchez-Pernaute, Olga, et al.
Publicado: (2021)

Why choose cyclosporin A as first-line therapy in COVID-19 pneumonia()
por: Sanchez-Pernaute, Olga, et al.
Publicado: (2021)

Oncogenic driver mutations in lung cancer
por: Luo, Susan Y, et al.
Publicado: (2013)

Biomarkers for Immunotherapy in Driver-Gene-Negative Advanced NSCLC
por: Huang, Yiyi, et al.
Publicado: (2023)

Targeted Therapy in Advanced and Metastatic Non-Small Cell Lung Cancer. An Update on Treatment of the Most Important Actionable Oncogenic Driver Alterations
por: König, David, et al.
Publicado: (2021)

Choosing the best heuristic for seeded alignment of DNA sequences
por: Sun, Yanni, et al.
Publicado: (2006)

How to choose the best journal for your case report
por: Rison, Richard A., et al.
Publicado: (2017)

PD-L1 expression and its relationship with oncogenic drivers in non-small cell lung cancer (NSCLC)
por: Jiang, Liyan, et al.
Publicado: (2017)

Insight into Oncogenic Viral Pathways as Drivers of Viral Cancers: Implication for Effective Therapy
por: Elkhalifa, Ahmed M. E., et al.
Publicado: (2023)

How do we choose the best donor for T-cell-replete, HLA-haploidentical transplantation?
por: Chang, Ying-Jun, et al.
Publicado: (2016)

RNA interference protocol to silence oncogenic drivers in leukemia cell lines
por: Beyer, Mandy, et al.
Publicado: (2022)

Choosing the right cell line for breast cancer research
por: Holliday, Deborah L, et al.
Publicado: (2011)

Osimertinib as first-line therapy in advanced NSCLC: a profile of its use
por: Scott, Lesley J.
Publicado: (2018)

Erratum to: How to choose the best journal for your case report
por: Rison, Richard A., et al.
Publicado: (2017)

A Method for Choosing the Best Samples for Mars Sample Return
por: Gordon, Peter R., et al.
Publicado: (2018)

Approaches to interpreting and choosing the best treatments in network meta-analyses
por: Mbuagbaw, L., et al.
Publicado: (2017)

Targeting MET Amplification as a New Oncogenic Driver
por: Kawakami, Hisato, et al.
Publicado: (2014)

RET Fusion: Joining the Ranks of Targetable Molecular Drivers in NSCLC
por: Osta, Badi El, et al.
Publicado: (2020)

Meta-Analysis of Therapy of Cinobufacini Capsule Adjunct with First-Line Platinum-Based Chemotherapy for the Treatment of Advanced NSCLC
por: Peng, Wenpan, et al.
Publicado: (2021)

Identification of candidates for driver oncogenes in scirrhous‐type gastric cancer cell lines
por: Sai, Eirin, et al.
Publicado: (2019)

Choosing the Right Life Partner: Ecological Drivers of Lichen Symbiosis
por: Vančurová, Lucie, et al.
Publicado: (2021)

Choosing the right cell line for renal cell cancer research
por: Brodaczewska, Klaudia K., et al.
Publicado: (2016)

Oncogenic drivers and mitochondrial dependency
por: Alvarez-Calderon, Francesca, et al.
Publicado: (2015)

Co-Occurring Potentially Actionable Oncogenic Drivers in Non-Small Cell Lung Cancer
por: Zhao, Yiming, et al.
Publicado: (2021)

Correction to: Osimertinib as first-line therapy in advanced NSCLC: a profile of its use
por: Scott, Lesley J.
Publicado: (2018)

Recent Progress in Rare Oncogenic Drivers and Targeted Therapy For Non-Small Cell Lung Cancer
por: Guo, Yijia, et al.
Publicado: (2019)

Use of liquid biopsy in monitoring therapeutic resistance in EGFR oncogene addicted NSCLC
por: Iacovino, Marialucia, et al.
Publicado: (2020)

Anti-PD1/PD-L1 Immunotherapy for Non-Small Cell Lung Cancer with Actionable Oncogenic Driver Mutations
por: Dantoing, Edouard, et al.
Publicado: (2021)

Choosing the Best Sensor Fusion Method: A Machine-Learning Approach
por: Brena, Ramon F., et al.
Publicado: (2020)

Splicing Dysregulation as Oncogenic Driver and Passenger Factor in Brain Tumors
por: Bielli, Pamela, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_sq3ggsqs8gqhf8e8i5ulv9ahpr